Evommune scraps eczema drug after mid-stage trial misses main goal
Evommune said it will not advance its experimental skin disease drug after failing to meet the main goal in a mid-stage trial, sending shares down 24% in aftermarket trading.
Evommune NYSE:EVMN said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.Here are some details